Veru Stock Price, News & Analysis

Veru Inc. (NASDAQ: VERU) reported fiscal Q2 2025 results and clinical progress for its enobosarm program. The company's Phase 2b QUALITY study showed positive results in combining enobosarm with GLP-1 RA drugs, demonstrating significant benefits in fat loss while preserving lean mass. Key findings include a 71% reduction in lean mass loss and improved body composition, with the 3mg dose showing >99% preservation of lean mass. The study revealed that enobosarm + semaglutide resulted in more selective fat loss (90.6%) compared to placebo + semaglutide (68%). Physical function tests showed significant improvements, with a 54.4% reduction in patients experiencing physical decline. Veru expects unblinded safety data and extension study results in Q2 2025, followed by an FDA End of Phase 2 meeting in Q3 2025. The company reported a net loss of $7.9 million ($0.05 per share) for Q2 2025.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company specializing in cardiometabolic and inflammatory disease treatments, has scheduled its fiscal 2025 second quarter financial results conference call and webcast for May 8, 2025, at 8:00 a.m. ET. The event will include a business update and can be accessed via audio webcast on the company's website at www.verupharma.com. Participants can join by phone using 1-800-341-1602 (domestic) or 1-412-902-6706 (international). A replay will be available online for three months and by phone for one week using passcode 7682749.

Veru Inc (NASDAQ: VERU) has announced its participation in the 2nd Annual GLP-1-Based Therapeutics Summit scheduled for April 29 - May 1, 2025, in Boston, Massachusetts. The company will present findings from their Phase 2b QUALITY Clinical Study focusing on how Enobosarm maintained lean mass and physical function in elderly patients using Semaglutide for weight loss.

The presentation is scheduled for April 30, 2025, at 12:30 PM EST at the Wyndham Boston Beacon Hill. This appearance aligns with Veru's focus on developing innovative medicines for cardiometabolic and inflammatory diseases.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company specializing in cardiometabolic and inflammatory disease treatments, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference.

Dr. Mitchell Steiner, the company's Chairman, President and CEO, will engage in a fireside chat at the conference on April 9, 2025, from 3:00 PM to 3:20 PM PDT in Las Vegas, Nevada. The recording will be made available on www.verupharma.com one day after the conference concludes. Interested parties can attend by contacting Jones Trading via mdoyle@jonestrading.com.

Veru Inc. (VERU) announced positive Phase 2b QUALITY study results for enobosarm combined with semaglutide (Wegovy). The study met its primary endpoint, showing a 71% reduction in lean mass loss, with enobosarm 3mg dose achieving >99% reduction. The treatment also demonstrated greater fat loss and improved physical function.

The company sold its FC2 Female Condom Business for $18 million, with estimated net proceeds of $12.3 million. Additionally, Veru announced a new cardiometabolic indication for sabizabulin to treat inflammation in atherosclerotic coronary artery disease.

Financial highlights include: R&D expenses increased to $5.7M from $1.7M, operating loss from continuing operations increased to $10.2M from $7.4M, and cash position stood at $26.6M as of December 31, 2024.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced it will host a conference call and audio webcast to discuss its fiscal 2025 first quarter financial results on Thursday, February 13, 2025, at 8:00 a.m. ET. The company focuses on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.

The audio webcast will be available on the company's website at www.verupharma.com under the Home page and Investors section. Participants can join via telephone by dialing 1-800-341-1602 (domestic) or 1-412-902-6706 (international). A replay will be available on the website for approximately three months, and a telephonic replay will be accessible for one week by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) with passcode 3764668.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company, which focuses on developing innovative medicines for muscle preservation in weight loss, oncology, and viral induced acute respiratory distress syndrome, will be represented by Mitchell Steiner, M.D., Chairman, President and CEO.

The presentation is scheduled for Tuesday, February 11, 2025, from 12:00 pm to 12:30 pm ET. The virtual event will be accessible through a live webcast on Veru's website (www.verupharma.com), with an archived version available for later viewing.

Veru (NASDAQ: VERU) announced positive topline results from its Phase 2b QUALITY clinical study evaluating enobosarm in combination with WEGOVY (semaglutide) for weight reduction. The study met its primary endpoint, demonstrating that enobosarm significantly preserved lean mass in patients receiving WEGOVY, with treated patients losing 71% less lean mass than those on WEGOVY alone.

Key findings include: patients on enobosarm lost 27% more fat mass than the control group, maintained similar total body weight loss, and showed reduced decline in physical function. The study involved 168 older patients (>60 years) over 16 weeks. In the placebo group, 32% of total weight loss was lean mass, while 42.6% experienced significant decline in stair climb power, compared to only 19.4% in the enobosarm group.

The company plans to proceed with Phase 3 trials following these positive results, with an anticipated sample size of 470 subjects over 52 weeks.

Veru Inc. (NASDAQ: VERU) has sold its FC2 Female Condom® business to clients managed by Riva Ridge Capital Management LP and co-investors for $18 million. The sale allows Veru to transform into a pure biopharmaceutical company, with estimated net proceeds of $12.5 million after deducting fees and premiums. The company will experience a significant workforce reduction of 90%, from 210 to 22 employees.

The company is currently focused on its Phase 2b QUALITY clinical trial evaluating enobosarm for muscle preservation and fat loss in patients using WEGOVY®, with topline results expected in January 2025. The transaction will also result in the termination of the Royalty Agreement with SWK Funding , eliminating $9.9 million in liabilities.